Kym is the CEO of Avivagen. He has extensive experience in capital markets, agriculture and life sciences. Kym is the current chair of Hybrid Partners and is the Executive Chair of Top Meadow Investments, Inc. He is also the previous chair of Prometic Life Sciences Inc.

Graham, a co-founder of Avivagen, comes with a background as a leading scientist in vitamin E research at the National Research Council of Canada (NRC). His later research activities became the foundation for Avivagen’s oxidized β-carotene technology.

David brings years of experience to Avivagen as the former President and CEO of Solvay Pharma Inc. He also co-founded a pharmaceutical distribution operation as VP of Kingswood Canada Inc. and has 15 years of experience in various positions at Eli Lilly.

Chief Executive Officer and Co-Founder, Crystal Research Associates LLC

Mr. Kraws ranks in the top ten analysts for pharmaceutical stock performance in the world, and Starmine and Zacks have both ranked him as number one stock picker for pharmaceuticals. His experience includes Senior Pharmeceutical Analyst at Evern Securities, Asea Brown Boveri, Nationsbanc Montgomery Securities, BT Alex Brown & Sons and The Buckingham Research Group Incorporated.

He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.

Mr. Aubrey Dan is a Canadian businessman, philanthropist and Tony-Award® winning producer (MEMPHIS) as well as the Principal of the Dancap Family Investment Office (dancap.ca).

Mr. Dan joined Novopharm Ltd. following his graduation from Western University in the role of Sales Representative, progressing to the position of Director of Sales. He later served as President of Wampole Canada Inc., a Novopharm subsidiary, until the acquisition of Novopharm by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA | TASE:TEVA) in 2000.

Mr. Paul Mesburis is the Managing Principal of Empyrean Capital, and has more than twenty years of international experience in financial and capital markets. On the buy-side, he has managed portfolios for global investment strategies in both debt and equities. On the sell-side, his experience includes senior roles in mergers and acquisitions, investment banking, and institutional equity research at HSBC Securities, Scotiabank Global Banking and Markets and Deutsche Bank Securities. In 2012, he was honoured with a Canadian Lipper Fund Award which recognizes funds that have excelled in delivering consistently strong risk-adjusted performance, relative to their peers.

Kym is the CEO of Avivagen. He has extensive experience in capital markets, agriculture and life sciences. Kym is the current chair of Hybrid Partners and is the Executive Chair of Top Meadow Investments, Inc. He is also the previous chair of Prometic Life Sciences Inc.

Graham, a co-founder of Avivagen, comes with a background as a leading scientist in vitamin E research at the National Research Council of Canada (NRC). His later research activities became the foundation for Avivagen’s oxidized β-carotene technology.

David brings years of experience to Avivagen as the former President and CEO of Solvay Pharma Inc. He also co-founded a pharmaceutical distribution operation as VP of Kingswood Canada Inc. and has 15 years of experience in various positions at Eli Lilly.

James joined Avivagen in 2007 to establish the company’s biological research facility and direct the R&D program as the senior research biologist. He later moved into the role of Director of Commercialization Science and Product Development. Now he is Executive VP of Business Development & Product Innovation, leading the business team and working with management to advance the global commercialization of the company’s products. James holds graduate degrees and postdoctoral research experience in the fields of molecular biology and physiology.

Tracy holds a Bachelor of Veterinary Science from the University of Queensland in Australia. She practiced as a veterinarian both with companion animals and in mixed animal practice in Australia and the UK for over a decade. She worked for Bayer Animal Health in New Zealand where she gained valuable experience within one of the world’s largest multinational pharmaceutical companies. Tracy moved to Canada in 2009 and has worked for Avivagen for the last 12 years.

Drew has 25 years in the investment industry including working on Fixed Income and Foreign Exchange desks (Merill Lynch Canada, Bankers Trust Canada. He has a B.A. Honours (Economics) from Queen’s University and an MBA (Finance & Marketing) from The Rotman School of Management (University of Toronto). Prior to joining Avivagen, he spent 15 years as an Institutional Equity Salesperson (Deutsche Bank, Levesque Beaubien), including holding the position of Head of Institutional Sales at Dundee Securities.

Munawara is an experienced business professional with 10+ years of office administrative experience, with extensive working knowledge of logistics operations, life sciences industry and public companies. She is a graduate of Algonquin College of Applied Arts and Technology. Munawara coordinates, plans, organizes and manages with key business executives and Avivagen’s partners supply chain operations to deliver Avivagen’s products safely and effectively to customers across the globe on time.

With a Bacherlor of Science in Biopharmaceutical Science and Masters of Science in Chemistry from the University of Ottawa, Trevor started with Avivagen in 2006 to carry out fundamental R&D related to OxC-betaTM technology. He is currently directing the Chemistry Group, with a lead role in Product Research and Development, Quality Control, and Regulatory Affairs.